Resistance to annexin A5 binding and anticoagulant activity in plasmas from patients with the antiphospholipid syndrome but not with syphilis [5]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 1, 2006, Pages 271-273

  Wu, X X ^a   Pierangeli, S S ^b   Rand, Jacob H ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c Core Laboratory Office ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BINDING ASSAY; BLOOD ANALYSIS; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; INCUBATION TIME; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; ROOM TEMPERATURE; STATISTICAL SIGNIFICANCE; SYPHILIS; BLOOD; BLOOD CLOTTING; METABOLISM; PHYSIOLOGY; PLASMA; PROTEIN BINDING;

ANNEXIN A5; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; HUMANS; PLASMA; PROTEIN BINDING; SYPHILIS;

EID: 33644868952     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01700.x     Document Type: Letter

References (11)

1. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth Young CG, Loizou S, Hughes GR. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4.
2. Moore JE, Mohr CF. The incidence and etiologic background of chronic biologic false-positive reactions in serologic tests for syphilis. Ann Intern Med 1952; 37: 1156-61.
3. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3: 285-6.
4. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73: 529-34.
5. Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 1100-4.
6. Reviakine I, Bergsma-Schutter W, Brisson A. Growth of protein 2-D crystals on supported planar lipid bilayers imaged in situ by AFM. J Struct Biol 1998; 121: 356-61.
7. Andree HAM, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM, Willems GM. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-12.
8. Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, Taatjes DJ. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: Evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163: 1193-200.
9. Rand JH, Wu XX, Lapinski R, van Heerde WL, Reutelingsperger CP, Chen PP, Ortel TL. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104: 2783-90.
10. Rand JH, Wu XX, Andree HAM, Alexander Ross JB, Rosinova E, Gascon-Lema MG, Calandri C, Harpel PC. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A 'lupus procoagulant' phenomenon. Blood 1998; 92: 1652-60.
11. Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005; 357: 17-33.